In the context of an aging population
Aging and life expectancy
We live in a context of aging populations and a significant increase in life expectancy. However, this extension is not always accompanied by a favorable quality of life. In an aggressive environment with a multitude of pollutants and attacks of various natures, we are witnessing a considerable increase in degenerative and also neuro-degenerative processes.
Degeneration of the organism and L-dopa
The degeneration linked to aging can be accelerated according to certain predispositions or environmental factors, such as pollution or stress. Experts estimate that we lose an average of 10% of dopaminergic neurons per decade and this from our 20 years with a decrease in our motor and cognitive faculties. Over time, the consequences of this degradation of the organism can be tremendous and be accompanied by a series of binding problems.
Oxidation of the body and Vitamin E
The aging of our organism is a complex process. Experts in this field have been studying for a few decades the fundamental reasons for this degeneration. In order to understand aging and study the possibility of slowing it down, a multitude of scientific teams around the world have carried out a very significant number of studies. Oxidative stress clearly crystallizes as one of the main vectors of the aging process. Indeed, it causes damage in our body through free radicals that attack the cells of the organism. Vitamin E then plays an essential role in the protection of cells, and more particularly of their membranes. This vitamin is not produced by our body and present in several foods and in particular some vegetables and oil oils.
A nutritional intake of 10 mg to 50 mg per day depending on age and sex is recommended. In 2012, the European health authorities (EFSA European Food Safety Authority and the European Commission) estimated that an intake of Vitamin E can contribute to the protection of cells against free radicals (antioxidant effects).
The targets of the scientific team
Slow down the degenerative processes related to age
One of the priorities of the scientific team: the development of a solution to support the body in its fight against aging and to slow down the degenerative processes linked to age.
Combat age-related motor problems
The other major objective: promoting life quality in the event of age-related motor problems such as rigidity, slowness of movement, tremors, imbalances, but also cognitive problems.
Develop a well-tolerated solution of natural origin
Finally, another important objective affirmed by the team has always been to be able to offer a solution of 100% natural origin that is very well tolerated by the body.
Preclinical studies and clinical studies
Various preclinical studies and clinical studies have been carried out and published during the last few years. The significant results of these scientific studies thus open the way to an innovative and natural approach for age-related problems and more specifically to dopaminergic deficits. The results of studies and the clinical trial carried out in excellent scientific standards confirm these choices: AtremoPlus was tolerated by 100% of the participants, with no undesirable side effects observed. Further studies have to be done to confirm these results over a very long period and with an increasing number of participants, but these findings are extremely encouraging at this stage.
Publication in scientific journals
The studies have been published (and commented) in the scientific journals below:
- " Journal of Genomic Medicine and Pharmacogenomics ". 2016 (Clinical trial)
- " Journal of Exploratory Research in Pharmacology " 2016
- " Clinical & Medical Biochemistry " 2016
- " Journal of Nutrition & Food Sciences " 2016
- "Alzheimers Disiease and Dementia" 2016
- " Royal Society of Chemistry " (book: Anti-aging Drugs: From Basic Research to Clinical Practice/A. Vaiserman/chapter 5.6.2) 2016
- " International Journal of Molecular Science " 2017 (Clinical trial)
- " Current pharmaceutical design " 2017
- " CNS Neuroscience & Therapeutics " 2017
- " Acta Biomed " 2017 (comment)
- " International Journal of Molecular Science " 2018
- " Current Medicinal Chemistry " 2018
- " Studies in Natural Products Chemistry " 2018 (book)
- " Planta med " 2019 (Clinical Trial)
- " Current Topics in Medicinal Chemistry" 2019
- " Current Neuropharmacology " 2019
- " Journal of Pharmaceutical Research International " 2019 (comment)
- " Current Pharmacogenomics and Personalized Medicine " 2020
- " Neuroscience Letters " 2020 (comment)
- " Nutrients" 2020
- " International Journal of Molecular Science " 2020
- " Drug Development Research " 2021
- " Medicinal Research Reviews" 2021 (Clinical Trial)
- " Nutraceuticals " 2021
- " Faba Bean: Chemistry, Properties and Functionality" 2022 (book)
- " Medicinal Plants for Cosmetics, Health and Diseases " 2022 (book)
- " International Journal of Molecular Science " 2022
- " Brain Sciences " 2022 (comment)
- " Pharmaceuticals" 2023
- " Genes " 2023
- " Biology " 2023
The results were also presented at the following scientific conferences:
« 6th conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics » Phoenix, USA 2016
« Drug Discovery and Therapy World Congress 2016 », Boston USA 2016
« 13th World congress of biological Psychiatry », Copenhagen 2017
« 7th conference on predictive, preventive and personalized medicine & molecular diagnostics » Chicago USA, 2017